Switzerland’s president rushes to Washington in effort to avert steep US tariffs

Switzerland's President is urgently in Washington to negotiate with the U.S. over a newly imposed 39% tariff on Swiss exports, including chocolates, machinery, and watches, a rate significantly higher than those for other trade partners. This steep tariff, justified by the U.S. citing a trade deficit, threatens to severely impact Swiss industries' competitiveness, prompting the Swiss government to prepare "new approaches" for discussions. The situation highlights the challenges of navigating unpredictable U.S. trade policy and its direct economic consequences for affected nations.

Analysis

Switzerland is facing a significant economic threat from a newly imposed 39% U.S. tariff on key exports, including machinery, watches, and chocolates, set to begin this week. This rate is substantially higher than tariffs on goods from the EU and UK, placing Swiss industries at a severe competitive disadvantage. The U.S. administration cites a trade deficit, with President Trump referencing a $41 billion figure, which contrasts slightly with the U.S. Census Bureau's reported $38.3 billion goods imbalance for the previous year. Swiss officials are in Washington for urgent negotiations, arguing that the tariffs are unjustified given Switzerland's status as the sixth-largest foreign investor in the U.S. and its near-zero tariffs on American goods. A critical element is the exemption of Switzerland's powerful pharmaceutical industry, including major players like Novartis (NVS). However, industry experts suggest this exemption may be temporary, with the steep tariffs on other goods serving as a warning shot to pressure Big Pharma. This introduces a latent risk for what is currently a protected sector, highlighting the unpredictable nature of the trade dispute and creating significant uncertainty for the Swiss economy pending the outcome of these high-stakes talks.

Key Decisions for Investors

• Investors with exposure to Swiss industrial sectors like machinery, watchmaking, and consumer goods should brace for significant margin pressure and potential downside volatility pending the outcome of U.S. trade negotiations.
• While Novartis (NVS) and the broader Swiss pharmaceutical sector are currently exempt from the 39% tariff, the situation serves as a warning, and investors should monitor for any change in U.S. policy that could remove this exemption and introduce significant risk.
• The high degree of uncertainty and political unpredictability surrounding the tariffs creates substantial event risk for the Swiss market, making it prudent for investors to review and potentially hedge their Swiss equity exposure until a resolution is achieved.